Mycosis fungoides and Sezary syndrome

Blood

Volumn 88, Issue 7, 1996, Pages 2385-2409

  Diamandidou, Eleni ^b   Cohen, Philip R ^b   Kurzrock, Razelle ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CANCER STAGING; CELL DIFFERENTIATION; ENVIRONMENTAL EXPOSURE; HELPER CELL; HISTOPATHOLOGY; HUMAN; LYMPHOCYTIC INFILTRATION; MAJOR HISTOCOMPATIBILITY COMPLEX; MYCOSIS FUNGOIDES; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SEZARY SYNDROME; T CELL LYMPHOMA;

EID: 0029822176     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v88.7.2385.bloodjournal8872385     Document Type: Review

References (296)

1. Alibert JLM: Tableau de plan fongoide: Description des maladies de la peau observee a l'hopital St. Louis, et exposition des meilleures methods suivies pour leur traitement. Paris, France, Barrior l'Aine et Files, 1806
2. Edelson RL: Cutaneous T-cell lymphoma: Mycosis fungoides, Sézary syndrome and other variants. J Am Acad Dermatol 2:89, 1980
3. Weinstock MA, Horn JW: Mycosis fungoides in the United States - Increasing incidence and descriptive epidemiology. JAMA 260:42, 1988
4. Epstein EH Jr, Levin DL, Croft JD Jr, Lutzner MA: Mycosis fungoides: Survival, prognostic features, response to therapy and autopsy findings. Medicine 51:61, 1972
5. Koch SE, Zackheim HS, Williams ML, Fletcher V, Leboit PE: Mycosis fungoides beginning in childhood and adolescence. J Am Acad Dermatol 17:563, 1987
6. Srivastana SBI, Banki K, Perl A: Human T-cell leukemia virus type I or a related retrovirus in patients with mycosis fungoides/ Sézary syndrome and Kaposi's sarcoma. Cancer Res 52:4391, 1992
7. Zucker-Franklin D, Pancake BA: The role of human T-cell lymphotropic viruses (HTLV-I/II) in cutaneous T-cell lymphomas: Semin Dermatol 13:160, 1994
8. Wantzin GL, Thomsen K, Nissen NI, Saxinger C, Gallo RC: Occurrence of human T-cell lymphotropic virus (type I) antibodies in cutaneous T-cell lymphoma. J Am Acad Dermatol 15:598, 1986
9. Manzari V, Gismondi A, Barillari G, Morrone S,Modesti A, Albonici L, De Marchis L, Fazio V, Gradilone A, Zani M, Frati L, Santoni AI: HTLV-V: A new human retrovirus isolated in a TAC-negative T-cell lymphoma/leukemia. Science 238:1581, 1987
10. Saxinger WC, Lange-Wantzin G, Thomsen K, Hoh M, Gallo RC : Occurrence of HTLV-I antibodies in Danish patients with cutaneous T-cell lymphoma. Scand J Hematol 34:455, 1985
11. Saal F, Gessain A, Lasneret J,Foldes C, Dronne P, Wallach D, Cottenot F, Sigaux F, Flandrin G, Peires J: Detection of retrovirus particles and reverse transcriptase activity in mid-term cultured peripheral blood and lymph node cells from a French woman with Sézary syndrome. Nouv Rev Fr Hematol 31:333, 1989
12. Detmar M, Pauli G, Anagnostopoulos I,Wunderlich U, Herbst H, Garbe C, Stein H, Orfanos CE : A case of classical mycosis fungoides associated with human T-cell lymphotropic virus type I. Br J Dermatol 124:198, 1991
13. Capecius C, Saal F, Maero E, Bazarbachi A, Lasneret J, Laroche L, Gessain A, Hojman F, Peries J: No evidence of HTLV-I infection in 24 cases of French and Portuguese mycosis fungoides/ Sézary syndrome. Leukemia 5:416, 1991
14. Kaltoft K, Bisballe S, Rasmussen HF, Thestrup-Pedersen K, Boehncke WH, Volker H, Sterry W: C-type particles are inducible in Se-Ax, a continuous T-cell line from a patient with Sézary syndrome. Arch Dermatol Res 280:264, 1988
15. Gallo RC, Kalyanaraman VS, Sarngadharan MG, Sliski A, Vonderheid EC, Maeda M, Nakao Y, Yamada K, Ito Y, Gutensonhn N, Murphy S, Bunn PA Jr, Catovsky D, Greaves MF, Blayney DW, Blattner W, Jarrett WFH, Zur Hausen H, Seligmann M, Brouet JC, Haynes BF, Jegasothy BV, Jaffe E, Cossman J, Broder S, Fisher RI, Golde DW, Robert-Guroff M: Association of the human type C retrovirus with a subset of adult T-cell cancers. Cancer Res 43:3892, 1983
16. Pancake BA, Zucker-Franklin D, Coutavas EE: The cutaneous T-cell lymphoma, mycosis fungoides, is a human T cell lymphotropic virus- associated disease. A study of 50 patients. J Clin Invest 95:547, 1995
17. Zucker-Franklin D, Coutavas EE, Rush MG,Zouzias DC: Detection of human T-lymphotropic virus-like particles in cultures of peripheral blood lymphocytes of patients with mycosis fungoides. Proc Ntl Acad Sci USA 88:7630, 1991
18. Hall WW, Liu CR, Schneewind O, Takahashi H, Kaplan MH, Roupe G, Vahlne A: Deteted HTLV-I provirus in blood and cutaneous lesions of patients with mycosis fungoides. Science 253:317, 1991
19. Lisby G, Reitz MS Jr, Vejlsgaard GL: No detection of HTLV-I DNA in punch skin biopsies from patients with cutaneous T-cell lymphoma by the polymerase chain reaction. J Invest Dermatol 98:417, 1992
20. D'Incan M, Bignon YJ, Souteyrand P, Roger H,Rance N, Dastugue B: Polymerase chain reaction (PCR) detection of an HTLV-1 DNA sequence in the genome of cutaneous T-cell lymphoma(CTCL) patients. J Invest Dermatol 94:393, 1990
21. Zucker-Franklin D, Hooper WC, Evatt BL: Human lymphotropic retroviruses associated with mycosis fungoides. Evidence that human T-cell lyphotropic virus type II(HTLV-II) as well as HTLV-I may play a role in the disease. Blood 80:1537, 1992
22. Nahass GT, Kraffert CA, Penneys NS: Cutaneous T-cell lymphoma associated with the acquired immunodeficiency syndrome. Arch Dermatol 127:1020, 1991
23. Crane GA, Variakojis D, Rosen ST, Sands AM, Roenigk HH Jr: Cutaneous T-cell lymphoma in patients with human immunodeficiency virus infection. Arch Dermatol 127:989, 1991
24. Lee LA, Huff JC, Edmond BJ, Weston WL,Norris DAI: Identification of herpes simplex virus antigens and DNA in lesions of mycosis fungoides. J Invest Dermatol 80:333, 1983
25. Duvic M, Magee K, Storthz KA: In situ hybridization for herpes simplex virus in mycosis fungoides and alopecia areata. J Invest Dermatol 92:423, 1989
26. Brice SL, Jester JD, Friednash M, Golitz LE, Leahy MA, Stockert SS, Weston W: Examination of cutaneous T-cell lymphoma for human herpesvirus by using the polymerase chain reaction. J Cutan Pathol 20:304, 1993
27. Lee PYP, Charley M, Tharp M, Jegasothy BV, Deng JS: Possible role of Epstein-Barr viral infection in cutaneous T-cell lymphoma. J Invest Dermatol 95:309, 1990
28. Limon J, Nedoszytko B, Brozek I, Hellmann A, Zajaczek S, Lubinski J, Mrozek K: Chromosome aberrations, spontaneous SCE, and growth kinetics in PHA-stimulated lymphocytes of five cases with Sézary syndrome. Cancer Genet Cytogenet 83:75, 1995
29. Lauritzen AF, Vejlsgaard GL, Hou-Jensen K, Ralfkiaer E: P53 protein expression in cutaneous T-cell lymphomas. Br J Dermatol 133:32, 1995
30. De Misa RF, Azana JM, Harto A, Bellas C, Ledo A: Infrequent expression of protein p53 in epidermotropic variants of cutaneous T-cell lymphoma. J Dermatol 22:524, 1995
31. McGregor JM, Dublin EA, Levison DA, MacDonald DM, Smith NP, Whttaker S: p53 immunoreactivity is common in primary cutaneous lymphoma. Br J Dermatol 132:353, 1995
32. Garatti SA, Roscetti E, Trecca D,Fracchiolla NS, Neri A, Berti E: bcl-1, bcl-2, p53,c-myc, and lyt-10 analysis in cutaneous lymphomas. Recent Results Cancer Res 139:249, 1995
33. Dummer R, Michie SA, Kell D, Gould JW, Haeffner AC, Smoller BR, Warnke RA, Wood GS: Expression of bcl-2 protein and ki-67 nuclear proliferation antigen in benign and malignant cutaneous T-cell infiltrates. J Cutan Pathol 22:11, 1995
34. Capocasale RJ, Lamb RJ, Vonderheid EC, Fox FE, Rook AH, Nowell PC, Moore JS: Reduced surface expression of transforming growth factor beta receptor type II in mitogen activated T-cells from Sézary patients. Proc Natl Acad Sci USA 92:5501, 1995
35. Hansen ER, Vejlsgaard GL, Lisby S, Heidenheim M, Baadsgaard O: Epidermal interleukin la functional activity and Interleukin 8 immunoreactivity are increased in patients with cutaneous T-cell lymphoma. J Invest Dermatol 97:818, 1991
36. Tron VA, Rosenthal D, Sauder DN: Epidermal interleukin-1 is increased in in cutaneous T-cell lymphoma. J Invest Dermatol 90:378, 1988
37. Wasik MA, Vonderheid EC, Bigler RD, Marti R, Lessin SR, Polansky M, Kadin ME: Increased serum concentration of the soluble interleukin-2 receptor in cutaneous T-cell lymphoma. Arch Dermatol 132:42, 1996
38. Rook AH, Heald P : The immunopathogenesis of cutaneous T-cell lymphoma. Hematol Oncol Clin North Am 9:997, 1995
39. Greene WC, Leonard WJ, Depper JM, Nelson DL, Waldmann TA: The human interleukin-2 receptor: Normal and abnormal expression in T-cells and in leukemias induced by the human T-lymphotropic retroviruses. Ann Intern Med 105:560, 1986
40. Kaudewitz P, Josimov9c Alasevic O, Dianantstein T, Eckert F, Klepzig K, Burg G: Soluble IL-2 receptor serum levies in cutaneous T-cell lymphoma: Correlation with clinical stage and IL-2 receptor status in cutaneous infiltrates. J Invest Dermatol 91:386, 1988
41. Bernengo MG, Fierro MT, Novelli M, Lisa F, Appino A: Soluble interleukin-2 receptor in Sézary syndrome: Its origin and clinical application. Br J Dermatol 128:124, 1993
42. Zachariae C, Larsen CS, Kaltoft K, Deleuran B, Larsen CG, Thestrup-Pedersen K: Soluble IL2 receptor serum levels and epidermal cytokines in mycosis fungoides and related disorders. Acta Derm Venereol 71:465, 1991
43. Szeimies RM, Rueff F, Kaudewitz P : Soluble Interleukin-2 receptor serum levels in mycosis fungoides. Cancer 70:2338, 1992
44. Van S-L, Heald P, Latkowski J, Edelson RL: Cytokine receptor expression on peripheral blood lymphocytes in Sézary syndrome. J Invest Dermatol 96:611, 1991 (abstr)
45. Camp R, Bacon K, Fincham N, Mistry K, Ross J, Lawlor F, Quinn D, Gearing A: Chemotactic cytokines in inflammatory skin disease. Adv Exp Med Biol 305:109,1991
46. Dalloul A, Laroche L, Bagot M, Mossalayi MD, Fourcade C, Thacker DJ, Hogge DE, Merie-Beral H, Debre P, Schmitt C: Interleukin-7 is a growth factor for Sézary lymphoma cells. J Clin Invest 90:1054, 1992
47. McLean-Wismer J, Mckenzie RC, Sauder D: Interleukin-8 immunoreactivity in epidermis of cutaneous T-cell lymphoma patients. Lymphokine Cytokine Res 13:21, 1994
48. Rook AH, Kubin M, Cassin M, Vonderheid EC, Vowels BR, Wolfe JT, Wolf SF, Singh A, Trinchieri G, Lessin SR: IL-12 reverses cytokine and immune abnormalities in Sézary syndrome. J Immunol 154:1491, 1995
49. Whittemore AS, Holly EA, Lee IM, Abel E, Adams RM, Nickoloff BJ, Bley L, Peters JM, Gibney C: Mycosis fungoides in relation to environmental exposure and immune response: A case-control study. J Natl Cancer Inst 81:1560, 1989
50. Fischmann AB, Bunn PA Jr, Guccion JG, Matthews MJ, Minna JD: Exposure to chemicals, physical agents, and biologic agents in mycosis fungoides/Sézary syndrome. Cancer Treat Rep 63:591, 1979
51. Greene MH, Dalager NA, Lamberg SI, Argyropoulos CE, Fraumeni JF Jr: Mycosis fungoides: Epidemiologic observations. Cancer Treat Rep 63:597, 1979
52. Cohen SR, Stenn KS, Braverman IM, Beck GJ: Mycosis fungoides: Clinicopathologic relationships, survival and therapy in 59 patients with observations on occupation as a new prognostic factor. Cancer 46:2654, 1980
53. Tuyp E, Burgoyne A, Aitchinson T, MacKie R: A case-control study of possible causative factors in mycosis fungoides. Arch Dermatol 163:196, 1987
54. Tokura Y, Yagi H, Ohshima A, Kurokawa S, Wakita H, Yokote R, Shirahama S, Furukawa F, Takigawa M: Cutaneous colonization with staphylococci influences the disease activity of Sézary syndrome: A potential role for bacterial superantigens. Br J Dermatol 133:6, 1995
55. Dick HM, Mackie R, DeSouza MB: HLA and Mycosis Fungoides: Proceeding of the First International Symposium on HLA and Disease. Paris, France, 1976, p 99
56. Mackie R, Dick HM, DeSouza MB: HLA and mycosis fungoides. Lancet 1:1179, 1976
57. Ryder LP, Anderson L, Svejgaard A (eds): HLA and disease registry - Third report. Tissue Antigens 15:1, 1979 (suppl 1)
58. Safai B, Myskowski PL, Dupont B, Pollack MS: Association of HLA-DR5 with mycosis fungoides. J Invest Dermatol 80:395, 1983
59. Griffiths CE, Voorhees JJ, Nickoloff BJ: Characterization of intercellular adhesion molecule-1 and HLA-DR expression in normal and inflammed skin: Modulation by recombinant gamma interferon and tumor necrosis factor. J Am Acad Dermatol 20:617, 1989
60. Nickoloff BJ, Griffiths CE, Baadsgaard O, Voorhees JJ, Hanson CA, Cooper KD: Markedly diminished epidermal keratinocyte expression of intercellular adhesion molecule-1(ICAM-1) in Sézary syndrome. JAMA 261:2217, 1989
61. Sandbank M, Katzenellenbogen I: Mycosis fungoides of prolonged duration in siblings. Arch Dermatol 98:620, 1968
62. Poiesz BJ, Ruscetti FW, Gazdar AF, Bunn PA, Minna JD, Gallo RC: Detection and isolation of type c retrovirus particles from fresh and cutlured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci USA 77:7415, 1980
63. Salahuddin SZ, Ablashi DV, Markham PD, Josephs SF, Sturzenegger S, Kaplan M, Halligan G, Biberfeld P, Wong-Staal F, Kramarsky B, Gallo RC: Isolation of a new virus, HBLV in patients with lymphoproliferative disease. Science 234:596, 1986
64. Slater D: Epstein-Barr virus: An aetiological factor in cutaneous lymphoproliferative disorders? J Pathol 65:1, 1991
65. Su IJ, Lin KH, Chen CJ, Tien HF, Hsieh HC, Lin DT, Chen JY: Epstein-Barr virus-associated peripheral T-cell lymphoma of activated CD8 phenotype. Cancer 66:2557, 1990
66. Su IJ, Hsieh HC, Lin KH, Uen WC, Kao CL, Chen CJ, Cheng AL, Kadin ME, Chen JY: Aggressive peripheral T-cell lymphomas containing Epstein-Barr viral DNA: A clinicopathologic and molecular analysis. Blood 77:799, 1991
67. Jones JF, Shurin S, Abramowsky C, Tubbs RR, Scitto CG, Wahl R, Sands J, Gottman D, Katz BZ, Sklar J: T-cell lymphomas containing Epstein-Barr viral DNA in patients with chronic Epstein-Barr viral infections. N Engl J Med 318:733, 1988
68. Pagano JS, Kenney S, Markovitz D, Kamine J: Epstein-Barr virus and interactions with human retroviruses. J Virol Methods 21:229, 1988
69. Zucker-Franklin D, Pancake BA, Friedman-Kien AE: Cutaneous disease resembling mycosis fungoides in HIV-infected patients whose skin and blood cells also harbor proviral HTLV type I. AIDS Res Hum Retroviruses 10:1173, 1994
70. Nasr SA, Brynes RK, Garrison CP, Chan WC: Peripheral T-cell lymphoma in a patient with acquired immune deficiency syndrome. Cancer 61:947, 1988
71. Presant CA, Gala K, Wiseman C, Kennedy P, Blayney D, Sheibani K, Winberg CD, Rasheed S: Human immunodeficiency virus-associated T-cell lymphoblastic lymphoma in AIDS. Cancer 60:1459, 1987
72. Ruff P, Bagg A, Papadopoulos K: Precursor T-cell lymphoma associated with human immunodeficiency virus type 1 (HIV-1) infection. First reported case. Cancer 64:39, 1989
73. Lust JA, Banks PM, Hooper WC, Paya CV, Kueck BD, Hanson GA, Ritch PS, Woloschak: T-cell non-Hodgkin's lymphoma in human immunodeficiency virus-1-infected individuals. Am J Hematol 31:181, 1989
74. Shah-Reddy I, Mayeda K, Mirchandani I, Koppitch FC: Sézary syndrome with a 14:14(q12:q31) translocation. Cancer 49:75, 1982
75. Neri A,Chang CC,Lombardi L, Salina M, Corradini P, Maiolo AT, Chaganti RSK, Dalla-Favera R: B-cell lymphoma-associated chromosomal translocation involves candidate oncogene lyt-10,homologous to NF-kB p50. Cell 67:1075, 1991
76. Cleary ML, Smith SD, Sklar J: Cloning and structural analysis of cDNAs for bcl-2 and a hybrid bcl-2/immunoglobulin transcript resulting from the t(14; 18) translocation. Cell 47:19, 1986
77. Hockenberry D, Nunez G, Milliman C, Schrieber RD, Korsmeyer SJ: Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 348:334, 1990
78. Dinarello CA: Biologic basis for interleukin-1 in disease. Blood 87:2095, 1996
79. Larsen CG, Anderson AO, Oppenheim JJ, Matsushima K: Production of interleukin-8 by dermal fibroblasts and keratinocytes in response to interleukin-1 or tumor necrosis factor. Immunology 68:31, 1989
80. Cooper KD, Hammerberg C, Baagdsgaard O, Elder JT, Chan LS, Sauder DN, Voorhees JJ, Fisher G: IL-1 activity is reduced in psoriatic skin: Decreased IL-1α and increased nonfunctional IL-1b. J Immunol 144:4593, 1990
81. Arend WP, Joslin FG, Thompson RC, Hannum CH: An IL-1 inhibitor from human monocytes. Production and characterization of biologic properties. J Immunol 143:1851, 1989
82. Bigler CF, Norris DA, Weston WL, Arend WP: Interleukin1 receptor antagonists: Production by human keratinocytes. J Invest Dermatol 98:38, 1992
83. Sica A, Matsushima K, Van Damme J, Wang JM, Polentarutti N, Dejana E, Colotta F, Mantovani A: IL-1 transcriptionally activates the neutrophil chemotactic factor/IL-8 gene in endothelial cells. Immunology 69:548, 1990
84. Osborn L, Hession C, Tizard R, Vassalo C, Luhowskyj S, Chi-Rosso G, Lobb R: Direct expression cloning of vascular cell adhesion molecule 1, a cytokine-induced endothelial protein that binds to lymphocytes. Cell 59:1203, 1989
85. Smith KA: The interleukin-2 receptor. Annu Rev Cell Biol 5:397, 1989
86. Symons JA, Wood NC, DiGiovine FS, Duff GW: Soluble IL-2 receptor in rheumatoid arthritis: Correlation with disease activity, IL-1 and IL-2 inhibition. J Immunol 141:2612, 1988
87. Dummer R, Posseckert G, Nestle F, Witzgall R, Burger M, Becker JC, Schafer E, Wiede J, Sebalt W, Burg G: Soluble interleukin-2 receptors inhibit interleukin-2 dependent proliferation and cytotoxicity: Explanation for diminished natural killer cell activity in cutaneous T-cell lymphomas in vivo? J Invest Dermatol 98:50, 1992
88. Charley MR, Chan LJ, Jegsothy BV: Cytokine effect on cutaneous T- cell leukemia (CTCL) cells: Specific proliferative response to IL-4 and IL-2. J Invest Dermatol 94:513, 1990 (abstr)
89. Saed G, Fivenson DP, Naidu Y, Nickoloff BJ: Mycosis fungoides exhibits a Th1-type cell-mediated cytokine profile whereas Sezary syndrome expresses a Th2-type profile. J Invest Dermatol 103:29, 1994
90. Wong CG, Clark SC: Multiple actions of interleukin 6 within a cytokine network. Immunol Today 9:137, 1988
91. Bacon K, Gearing A, Camp R: Induction of in vitro human lymphocyte migration by interleukin 3, interleukin 4, and interleukin 6. Cytokine 2:100, 1990
92. Lawlor F, Smith NP, Camp RDR, Bacon KB, Black AK, Greaves MW, Gearing AJH: Skin exudate levels of interleukin 6, interleukin 1 and other cytokines in mycosis fungoidees. Br J Dermatol 123:297, 1990
93. Henney CS: Interleukin 7: Effects on early events in lymphopoeisis. Immunol Today 10:170, 1989
94. Nickoloff BJ, Griffiths CEM: Intraepidermal but not dermal T-lymphocytes are positive for a cell-cycle-associated antigen (ki-67) in mycosis fungoides. Am J Pathol 136:261, 1990
95. Stingl G, Tamaki K, Katz SI: Origin and function of epidermal Langerhans cells. Immunol Rev 53:149, 1980
96. Tjernlund UM: Epidermal expression of HLA-DR antigens in mycosis fungoides. Arch Dermatol Res 261:8186, 1978
97. Verga M, Braveman M: The use of immunohistologic analysis in differentiating cutaneous T-cell lymphoma from psoriasis and dermatitis. Arch Dermatol 127:1503, 1991
98. Hansen ER: Immunoregulatory events in the skin of patients with cutaneous T-cell lymphoma. Arch Dermatol 132:555, 1996
99. MacDonald DM: Histopathological differentiation of benign and malignant cutaneous lymphocytic infiltrates. Br J Dermatol 107:715, 1982
100. Hoppe RT, Wood GS, Abel EA: Mycosis fungoides and the Sézary syndrome: Pathology,staging, and treatment. Curr Probl Cancer 14:293, 1990
101. Willemze R, Beljaards RC, Meijer CJLM: Classification of primary cutaneous T-cell lymphomas. Histopathology 24:405, 1994
102. Blasik LG, Newkirk RE, Dimond RL, Clendenning WE: Mycosis fungoides d'emblee: A rare presentation of cutaneous T-cell lymphoma. Cancer 49:742, 1982
103. Wieselthier JS, Koh HK: Sézary syndrome: Diagnosis, prognosis, and critical review of treatment options. J Am Acad Dermatol 22:381, 1990
104. Prunieras M: Le syndrome et la cellule de Sézary. Dermatologica 157:371, 1978
105. Schechter GP, Sausville EA, Fischmann AB: Evaluation of circulating malignant cells provides prognostic information in cutaneous T-cell lymphoma. Blood 69:841, 1987
106. Heald P, Edelson RL: Cutaneous T-cell lymphomas, in Hoffman R, Benz EJ Jr, Shattil SJ, Furie B, Cohen HJ (eds): Hematology: Basic Principles and Practice. New York, NY, Churchill Livingston, 1991, p 1008
107. Hoppe RT, Cox RS, Fuks Z, Price NM, Bagshaw MA, Farber EM: Electron-beam therapy for mycosis fungoides: The Standford University experience. Cancer Treat Rep 63:691, 1979
108. Matthews MJ: Surgical pathology of mycosis fungoides and Sézary syndrome, in Jaffe ES (ed): Surgical Pathology of the Lymph Nodes and Related Organs. Philadelphia, PA, Saunders, 1985, p 329
109. Hoppe RT, Abel EA, Deneau DG, Price NM: Mycosis fungoides: Management with topical nitrogen mustard. J Clin Oncol 5:1796, 1987
110. Patel DJ, Greim ML, Vijayakumar S, Griem SF: Treatment of pulmonary mycosis fungoides with whole-lung radiation therapy. J Surg Oncol 38:118, 1988
111. Greer KE, Legum LL, Hess LE: Multiple osteolytic lesions in a patient with mycosis fungoides. Arch Dermatol 113:1242, 1977
112. Bunn PA, Huberman MS, Whang-Peng J, Schechter GP, Guccion JG, Matthews MJ, Gazdar AF, Dunnick NR, Fischmann AB, Ihde DC, Cohen MH, Fossiek B, Minna JD: Prospective staging evaluation of patients with cutaneous T cell lymphomas. Ann Intern Med 93:223, 1980
113. Kuzel TM, Roenigk HH Jr, Rosen ST: Mycosis fungoides and Sézary Syndrome: A review of pathogenesis, diagnosis, and therapy. J Clin Oncol 9:1298, 1991
114. Harris NL, Jaffe ES, Stein H, Bands PM, Chan JKC, Cleary ML, Delsol G, De Wolf-Peeters C, Falini B, Gatter KC, Grogan TM, Isaacson PG, Knowles DM, Mason DY, Muller-Hermelink HK, Pileri SA, Piris MA, Ralfkiaer E, Warnke RA: A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group. Blood 84:1361, 1994
115. Long JC, Mihm MC: Mycosis fungoides with extracutaneous dissemination: A distinct clinicopathologic entity. Cancer 34:1745, 1974
116. Shapiro PE, Pinto FJ: The histologic spectrum of mycosis fungoides/Sézary syndrome (cutaneous T-cell lymphoma). Am J Surg Pathol 18:645, 1994
117. Everett MA: Early diagnosis of mycosis fungoides: Vacuolar interface dermititis. J Cutan Pathol 12:271, 1985
118. Sanchez JL, Ackerman AB: The patch stage of mycosis fungoides. Criteria for histologic diagnosis. Am J Dermatopathol 1:5, 1979
119. Nickoloff BJ: Light-microscopic assessment of 100 patients with patch/plaque stage mycosis fungoides. Am J Dermatopathol 10:469, 1988
120. Wood CS, Weiss LM, Warnke RA, Sklar J: The immunopathology of cutaneous lymphomas: Immunophenotypic and immunogenotypic characteristics. Semin Dermatol 5:334, 1986
121. Michie SA, Abel EA, Hoppe RT, Warnke RA, Wood GS: Expression of T -cell receptor antigens in mycosis fungoides and inflammatory skin lesions. J Invest Dermatol 93:116, 1989
122. Wood GS, Hong SR, Sasaki DT, Abel EA, Hoppe RT, Warnke RA, Morhenn VB: Leu/CD7 antigen expression by CD3+ T-cells: Comparative analysis of skin and blood in mycosis fungoides/Sézary syndrome relative to normal blood values. J Am Acad Dermatol 22:602, 1990
123. Aguarsson BA, Vonderheid EC, Kadin ME: Cutaneous T-cell lymphomas with suppressor/cytoxic (CD8) phenotype: Identification of rapidly progressive and chronic subtypes. J Am Acad Dermatol 22:569, 1990
124. Michie SA, Abel EA, Hoppe RT, Warnke RA, Wood GSI: Discordant expression of antigens between intraepidermal and intradermal T-cells in mycosis fungoides. J Invest Dermatol 137:1447, 1990
125. Bagot M, Wechsler J, Lescs M-C, Revuz J, Parcet J-P, Gaulard P: Intraepidermal localization of the clone in cutaneous T-cell lymphoma. J Am Acad Dermatol 27:589, 1992
126. Hunt SJ, Charley MR, Jegasothy BV: Cutaneous T-cell lymphoma: Utility of antibodies to the variable regions of the human T-cell antigen receptors. J Am Acad Dermatol 26:552, 1992
127. Fivenson DP, Hanson CA, Nickoloff BJ: Specific localization of the malignant clone to the epidermal compartment of cutaneous T-cell lymphoma. Clin Res 40:308A, 1992 (abstr)
128. Ralfkiaer E, O'Connor NTJ, Crick J, Wantzin GL, Mason DY: Genotypic analysis of cutaneous T-cell lymphomas. J Invest Dermatol 88:762, 1987
129. Dosaka N, Tanaka T, Fugita M, Miyachi Y, Horio T, Imamura S: Southern blot analysis of clonal rearrangements of the T-cell receptor gene in plaque lesions of mycosis fungoides. J Invest Dermatol 93:626, 1989
130. Wood GS, Liao S, Crooks CF, Sklar J: Cutaneous lymphoid infiltrates: Analysis by polymerase chain reaction and denaturing gradient gel electrophoresis (PCR/DGGE). J Invest Dermatol 98:553, 1992 (abstr)
131. Nakajima N, Tanaka T, Miyachi S, Imamura S, Kakizuka A: Characterization of the lymphoproliterative disease in the skin by DNA analysis. J Dermatol 18:627, 1991
132. Wood GS: The benign and malignant cutaneous lymphoproliferative disease including mycosis fungoides, in Knowles DM (ed): Neoplastic Hematopathology. Baltimore, MD, Williams and Wilkins, 1992, p 917
133. Lambert WC, Everett MA: The nosology of parapsoriasis. J Am Acad Dermatol 5:373, 1981
134. Lindae ML, Abel EA, Hoppe RT, Wood GS: Poikilodermatous mycosis fungoides and atrophic large plaque parapsoriasis exhibit similar abnormalities of T-cell antigen expression. Arch Dermatol 124:366, 1988
135. Staib G, Sterry W: Use of polymerase chain reaction in the detection of clones in lymphoproliferative diseases of the skin. Recent Results Cancer Res 139:239, 1995
136. Woringer F, Kolopp P: Lesion erythemato-squameuse polycyclique de l'avantbras evoluante depuis 6ans chez un garconnet de 13 ans, Histologiquement infutratintra-epidermique d'apparence tumorale. Ann Dermatol Symp 10:945, 1939
137. Ketron LW, Goodman MH: Multiple lesions of skin apparently at epithelial origin resembling clinically mycosis fungoides: Report of a case. Arch Dermatol Syph 24:758, 1931
138. Wood WS, Killby VAA, Steward WD: Pagetoid reticulosis (Woringer-Kolopp disease). J Cutan Pathol 6:113, 1979
139. Wood GS, Weiss LM, Hu CH, Abel EA, Hoppe RT, Warnke RA, Sklar J: T-cell antigen deficiencies and clonal rearrangements of T-cell receptor genes in pagetoide reticulosis (Woringer-Kolopp disease). N Engl J Med 318:164, 1988
140. Lacour JP, Juhlin L, el Baze P, Barety M, Ortonne JP: Disseminated pagetoid reticulosis associated with mycosis fungoides: Immunomorphologic study. J Am Acad Dermatol 14:898, 1986
141. Burns MK,Chan LS, Cooper KD: Woringer-Kolopp disease (localized pagetoid reticulosis) or unilesional mycosis fungoides? An analysis of eight cases with benign disease. Arch Dermatol 131:325, 1995
142. Mielke V, Wolff HH, Winzer M, Sterry W: Localized and disseminated pagetoid reticulosis: Diagnostic immunophenotypical findings. Arch Dermatol 125:402, 1989
143. Leboit PE, Beckstead JH, Bond B, Epstein WL, Frieden IJ, Parslow TG: Granulomatous slack skin: Clonal rearrengement of the T-cell receptor β gene is evidence for the lymphoproliferative nature of a cutaneous elastolytic disorder. J Invest Dermatol 89:183, 1987
144. Macaulay WL: Lymphomatoid papulosis: A continuing self-healing eruption, clinically benign-histologialloy malignant. Arch Dermatol 97:23, 1968
145. El-Azhary RA, Gibson LE, Kurtin PJ, Pittelkow MR, Muller SA: Lymphomatoid papulosis: A clinical and histopathologic review of 53 cases with leukocyte immunophenotyping, DNA flow cytometry and T-cell receptor gene rearrangement studies. J Am Acad Dermatol 30:210, 1994
146. Willemze R, Meyer CJ, Van Vloten WA, Scheffer E: The clinical and histological spectrum of lymphomatoid papulosis. Br J Dermatol 107:131, 1982
147. Weiss LM, Wood GS, Trela M, Warnke RA, Sklar J: Clonal T-cell population in lymphomatoid papulosis: Evidence of a lymphoproliferative origin for a clinical benign disease. N Engl J Med 315:475, 1986
148. Knowles DM: Immunophenotypic and antigen receptor gene rearrangement analysis in T cell neoplasia. Am J Pathol 134:761, 1989
149. Brehmer-Andersson E: Mycosis fungoides and its relation to Sézary syndrome, lymphomatoid papulosis, and primary cutaneous Hodgkin's disease. A clinical, histopathologic and cytologic study of fourteen cases and a critical review of the literature. Acta Derm Venereol 56:3, 1979 (suppl)
150. Sanchez NP, Pittelkow MR, Muller SA, Bank PM, Winkelmann RK: The clinicopathologic spectrum of lymphomatoid papulosis: Study of 31 cases. J Am Acad Dermatol 8:81, 1983
151. Cabanillas F, Armitage J, Pugh WC, Weisenburger D, Duvic M: Lymphomatoid papulosis: A T-cell dyscrasia with a propensity to transform into malignant lymphoma. Ann Intern Med 122:210, 1995
152. Pinkus H: Alopecia mucinosa: Inflammatory plaques with alopecia characterized by root-sheath mucinosis. Arch Dermatol 76:419, 1957
153. Mehregan DA, Gibson LE, Muller SA: Follicular mucinosis: Histopathologic review of 33 cases. Mayo Clin Proc 66:387, 1991
154. Zelickson BD, Peters MS, Muller SA, Thibodeau SN, Lust JA, Quam LM, Pittelkow MR: T-cell receptor gene rearrangement analysis: Cutaneous T-cell lymphoma, peripheral T-cell lymphoma, and premalignant and benign cutaneous lymphoproliferative disorders. J Am Acad Dermatol 25:787, 1991
155. Binnick AN, Wax FD, Clendenning WE: Alopecia mucinosa of the face associated with mycosis fungoides. Arch Dermatol 114:791, 1978
156. Wilkinson JD, Black MM, Chu A: Follicular mucinosis associated with mycosis fungoides presenting with gross cystic changes on the face. Clin Exp Dermatol 7:333, 1982
157. Kanno S, Niizuma K, Machida S, Takahashi M, Ohkido M, Nagura H, Murakosi M, Mori T: Follicular mucinosis developing into cutaneous lymphoma: Report of two cases and review of the literature and 64 cases in Japan. Acta Derm Venereol 64:86, 1984
158. Plotnick H, Abbrecht M: Alopecia mucinosa and lymphoma. Arch Dermatol 92:137, 1965
159. Lacour JP, Castanet J, Perrin C, Ortonne JP: Follicular mycosis fungoides: A clinical and histologic variant of cutaneous T-cell lymphoma: Report of two cases. J Am Acad Dermatol 29:330, 1993
160. Ralfkiaer E, Wantzin GL, Stein H, Mason DY: Photosensitive dermatitis with actinic reticuloid syndrome: An immunohistological study of the cutaneous infiltrate. Br J Dermatol 114:47, 1986
161. Toonstra J, Henquet CJ, van Weelden H, van der Putte SC, van Vloten WA: Actinic reticuloid: A clinical, photobiologic, histopathologic and follow-up study of 16 patients. J Am Acad Dermatol 21:205, 1989
162. Chu AC, Robinson D, Hawk JLM, Meacham R, Spittle MF, Smith NP: Immunologic differentiation of the Sézary syndrome due to cutaneous T-cell lymphoma and chronic actinic dermatitis. J Invest Dermatol 86:134, 1986
163. Watsky MS, Lynfield YL: Poikiloderma vasculare atrophicans. Cutis 17:938, 1976
164. Samman PD: The natural history of parapsoriasis en plaques (chronic superficial dermatitis) and prereticulotic poikiloderma. Br J Dermatol 87:405, 1972
165. Toonstra J: Jessner's lymphocytic infiltrate, in Arndt KA, Leboit PE, Robinson JK, Wintroub BU (eds): Cutaneous Medicine and Surgery. Philadelphia, PA, Saunders, 1996, p 344
166. Bignon YJ, Souteyrand P: Genotyping of cutaneous T-cell lymphomas and pseudolymphomas. Curr Probl Dermatol 19:114, 1990
167. Headington JT, Roth MS, Ginsburg D, Lichter AS, Hyder D, Schnitzer B: T-cell receptor gene rearrangement in regressing atypical histiocytosis. Arch Derm 123:1183, 1987
168. Rijlaarsdam JU, Scheffer E, Meijer CJL, Willemze R: Cutaneous pseudo-T-cell lymphomas. Cancer 69:717, 1992
169. Beljaards RC, Kaudewitz P, Berti E, Gianotti R, Neumann C, Rosso R, Pauli M, Meijer CJLM, Willemze R: Primary cutaneous CD30-positive large cell lymphoma: Definition of a new type of cutaneous lymphoma with a favorable prognosis: A European multicenter study of 47 patients. Cancer 71:2097, 1993
170. Kaudewitz P, Stein H, Dallenbach F, Eckert F, Bieber K, Burg G, Braun-Falco O: Primary and secondary cutaneous Ki1+(CD30+) anaplastic large cell lymphomas. Am J Pathol 135:359, 1989
171. Banerjee SS, Heald J, Harris M: Twelve cases of Ki-1 positive anaplastic large cell lymphoma of the skin. J Clin Pathol 44:119, 1991
172. Beljaards RC, Willemze R: The prognosis of patients with lymphomatoid papulosis associated with malignant lymphomas. Br J Dermatol 126:596, 1992
173. Beljaards RC, Meijer CJLM, Scheffer E, Toonstra J, Van Vloten WA, Van der Putte SCJ, Geerts ML, Willemze R: Prognostic significance of CDSO(Ki-1/BerH2) expression in primary cutaneous large cell lymphomas of T-cell origin: A clinicopathologic and immunohistochemical study in 20 patients. Am J Pathol 135:1169, 1989
174. Salhany KE, Cousar JB, Greer JP, Casey TT, Fields JP, Collins RD: Transformation of cutaneous T-cell lymphoma to large cell lymphoma: A clinicopathologic and immunohistologic study. Am J Pathol 132:265, 1988
175. Nagatani T, Kim S, Baba N, Minato K, Shimoyama M, Nakajima H: Phenotypic heterogeneity of lymphoma of the skin. J Dermatol 16:443, 1989
176. Shimoyama M, Minato K, Saito H: Comparison of clinical, morphologic and immunologic characteristics of adult T-cell leukemia- lymphoma and cutaneous T-cell lymphoma. Jpn J Clin Oncol 9:357, 1979 (suppl)
177. Shimoyama M: Monoclonal antibodies and immunodiagnosis of leukemia/lymphoma. Acta Haematol Jpn 48:1711, 1985
178. Haynes BF, Metzgar RS, Minna JD, Bunn PA: Phenotypic characterization of cutaneous T-cell lymphoma: Use of monoclonal antibodies to compare with other malignant T cells. N Engl J Med 304:1319, 1981
179. Van der Putte SCJ, Toonstra J, Van Wichen DF, Van Unnik JAM, Van Vloten WA: Aberrant immunophenotypes in mycosis fungoides. Arch Dermatol 124:373, 1988
180. Shirono K, Hattori T, Hata H, Nishimura H, Takatsuki K: Profiles of expression of activated cells from different clinical stages of adult T-cell leukemia. Blood 73:1664, 1989
181. The T- and B-cell Malignacy Study Group: Statistical anayses of clinico-pathological, virological and epidemiological data on lymphoid malignacies with special reference to adult T-cell leukemia/lymphoma: A report of second nationwide study in Japan. Jpn J Clin Oncol 15:517, 1985
182. The T- and B-cell Malignacy Study Group: The third nation-wide study on adult T-cell leukemia/lymphoma (ATL) in Japan: Characteristic patterns of HLA antigen and HTLV-I infection in ATL patients and their relatives. Int J Cancer 41:505, 1988
183. Uchiyama T, Yodoi J, Sagawa K, Takatsuki K: Adult T-cell leukemia: Clinical and hematologic features of 16 cases. Blood 50:481, 1977
184. Lennert K, Kikuchi M, Sato E, Suchi T, Stansfeld AG, Feller AC, Hansmann ML, Muller-Hermelink K, Godde-Salz E: HTLV-positive and -negative T-cell lymphomas. Morphological and immunohistochemical differences between European and HTLV-positive Japanese T-cell lymphomas. Int J Cancer 35:65, 1985
185. Nasu K, Said J, Vonderheid E, Olerud J, Sako D, Kadin M: Immunopathology of cutaneous T-cell lymphomas. Am J Pathol 119:436, 1985
186. Tanaka T, Takahashi K, Ideyama S,Imamura S, Noma T: Demonstration of clonal proliferation of T-lymphocytes in early neoplastic disease. Studies with probes for the beta-chain of the T-cell receptor and human T-cell lymphotropic virus type I. J Am Acad Dermatol 21:218, 1989
187. Vose JM,Weisenburger DD, Sanger WG,Bierman PJ, Armitage JO: Peripheral T-cell lymphoma - A brief review. Leuk Lymphoma 3:77, 1990
188. Chott A, Augustin I, Wrba F, Hanak H, Ohlinger W, Radasz-kiewicz TI: Peripheral T-cell lymphomas: A clinicopathologic study of 75 cases. Hum Pathol 21:1117, 1990
189. Lukes RJ, Collins RD: Immunologic characterization of human malignant lymphomas. Cancer 34:1488, 1974
190. Greer JP, Salhany KE, Cousar JB, Fields JP, King LE, Graber SE, Flexner JM, Stein RS, Collins RD: Clinical features associated with transformation of cerebriform T-cell lymphoma to a large cell process. Hematol Oncol 8:215, 1990
191. Dmitrovsky E, Matthews MJ, Bunn PA, Schechter GP, Makush RW, Winkler CF, Eddy J, Sausville EA, Ihde DC: Cytologic transformation in cutaneous T-cell lymphoma: A clinicopathologic entity associated with poor prognosis. J Clin Oncol 5:208, 1987
192. Cerroni L, Rieger E, Hodl S, Kerl H: Clinicopathologic and immunologic features associated with transformation of mycosis fungoides to large cell lymphoma. Am J Surg Pathol 16:543, 1992
193. Foss FM, Sausville EA: Prognosis and staging of cutaneous T-cell lymphoma. Hematol Oncol Clin North Am 9:1011, 1995
194. Minna JD, Roenigh HH Jr, Glatstein E: Report of the committee on therapy for mycosis fungoides and Sézary syndrome. Cancer Treat Rep 63:729, 1979
195. Lamberg SI, Green S, Byar D, Block J, Vonderheid E: Clinical staging for cutaneous T-cell lymphoma. Ann Intern Med 100:187, 1984
196. Lamberg SI, Green SB, Byar DP, Block JB, Clendenning WE, Epstein EH, Fuks ZY, Golitz LE, Lorincz AL, Michel B, Roenigk HH, Van Scott EJ, Vonderheid EC, Thomas RJ: Status report of 376 mycosis fungoides patients at 4 years: Mycosis Fungoides Cooperative Group. Cancer Treat Rep 63:701, 1979
197. Bunn PA, Lambert SI: Report of the committee on staging and classification of cutaneous T-cell lymphomas. Cancer Treat Rep 63:725, 1979
198. Green S, Byar D, Lamberg S: Prognostic variables in mycosis fungoides. Cancer 47:2671, 1981
199. Kim YH, Bishop K, Varghese A, Hoppe RT: Prognostic factors in erythrodermic mycosis fungoides and the Sézary syndrome. Arch Dermatol 131:1003, 1995
200. Sausville EA, Eddy JL, Makuch RW, Fischmann AB, Schechter GP, Matthews M, Glatstein E, Ihde DC, Kaye F, Veach SR, Phelps R, O'Connor T, Trepel JB, Cotelingam JD, Gazdar AF, Minna JD, Bunn PA Jr: Histopatholgoic staging at initial diagnosis of mycosis fungoides and Sézary syndrome. Definitions of three distinctive prognostic groups. Ann Intern Med 109:372, 1988
201. Sausville EA, Worsham GF, Matthews MJ, Makuch RW, Fischmann AB, Schechter GP, Gazdar AF, Bunn PA Jr: Histopathologic assessment of lymph nodes in mycosis fungoides/Sézary syndrome (cutaneous T-cell lymphoma): Clinical correlations and prognostic import of a new classification system. Hum Pathol 16:1098, 1985
202. Vonderheid EC, Diamond LW, Lai SM, Au F, Dellavecchia MA: Lymph node histopathologic findings in cutaneous T-cell lymphoma. Am J Clin Pathol 97:121, 1992
203. Vonderheid EC, Diamond LW, Van Vloten WA, Scheffer E, Meijer CJLM, Cashell AW, Hardman JM, Lai SM, Hermans J, Matthews MJ: Lymph node classification systems in cutaneous T-cell lymphomas. Cancer 73:207, 1994
204. Fuks ZY, Bagshaw MA, Farber EM: Prognostic signs and the management of the mycosis fungoides. Cancer 32:1385, 1973
205. Hoppe RT, Medeiros LJ, Warnke RA, Wood GS: CD-8 positive tumor-infiltrating lymphocytes influence the long-term survival of patients with mycosis fungoides. J Am Acad Dermatol 32:448, 1995
206. Marti RM, Estrach T, Reverter JC, Mascaro JM: Prognostic clinicopathologic factors in cutaneous T-cell lymphoma. Arch Dermatol 127:1511, 1991
207. Abel EA, Wood GS, Hoppe RT: Mycosis fungoides: Clinical and histologic features, staging,evaluation, and approach to treatment. CA Cancer J Clin 43:93, 1993
208. Vonderheid EC: Topical mechlorethamine chemotherapy: Considerations on its use in mycosis fungoides. Int J Dermatol 23:180, 1984
209. Vonderheid EC, Tan ET, Kantor AF, Shrager L, Micaily B, Van Scott EJ: Long term efficacy, curative potential, and carcinogenicity of topical mechlorethamine chemotherapy in cutaneous T-cell lymphomas. Am Acad Dermatol 20:416, 1989
210. Ramsay DL, Halperin PS, Zeleniuch-Jacquotte A: Topical mehlorethamine therapy for early stage mycosis fungoides. J Am Acad Dermatol 19:684, 1988
211. Honigsmann H, Brenner W, Rauschmeier W, Konrad K, Wolff K: Photochemotherapy for cutaneous T-cell lymphomas: A follow-up study. J Am Acad Dermatol 10:238, 1984
212. Briffa DV, Warin AP, Harrington CI, Bleehen SS: Photochemotherapy in mycosis fungoides. Lancet 12:49, 1980
213. Herrmann JJ, Roenigk HH Jr, Hurria A, Kuzel TM, Samuelson E, Rademaker AW, Rosen ST: Treatment of mycosis fungoides with photochemotherapy (PUVA): Long-term follow-up. J Am Acad Dermatol 33:234, 1995
214. Roenigk H: Photochemotherapy for mycosis fungoides: Long term follow-up study. Cancer Treat Rep 63:669, 1979
215. Lowe NJ, Cripps DJ, Dufton PA, Vickers CF: Photochemotherapy for mycosis fungoides. Arch Dermatol 115:50, 1979
216. Powel FC, Spiegel GT, Muller SA: Treatment of parapsoriasis and mycosis fungoides: The role of psoralen and long-wave ultraviolet light A (PUVA). Mayo Clin Proc 59:538, 1984
217. Honigsmann H, Tanew A, Wolff K: Treatment of mycosis fungoides with PUVA. Photodermatology 4:55, 1987
218. Rosenbaum MM, Roenigk HH Jr, Caro WA, Esker A: Photochemotherapy in cutaneous T-cell lymphoma and parapsoriasis en plaques. Long-term follow-up in forty-three patients. J Am Acad Dermatol 13:613, 1985
219. Abel EA, Sendagorta E, Hoppe RT, Hu CH: PUVA therapy of erythrodermic and plaque-type mycosis fungoides. Arch Dermatol 123:897, 1987
220. Molin L, Thomsen K, Volden G, Groth O: Photochemotherapy (PUVA) in the pretumor stage of mycosis fungoides. A report from Scandinavian mycosis fungoides study group. Acta Dermatol Venereol 61:47, 1981
221. Molin L, Thomsen K, Volden G, Groth O: Photochemotherapy (PUVA) in the tumor stage of mycosis fungoides: A report from Scandinavian mycosis fungoides study group. Acta Dermtol Venereol 61:52, 1981
222. Roenigk HH, Kuzel TM, Skoutelis AP, Springer E, Yu G, Caro W, Gilyon K, Variakotjis D, Kaul K, Bunn PA Jr, Evans L, Rosen ST: Photochemotherapy alone or combined with interferon alpha-2a in the therapy of cutaneous T-cell lymphoma. J Invest Dermatol 95:198S, 1990 (suppl)
223. Du Vivier A, Vollum DI: Photochemotherapy and topical nitrogen mustard in the therapy of mycosis fungoides. Br J Dermatol 102:319, 1980
224. Bunn PA Jr, Hoffman SJ, Norris D, Golitz LE, Aeling JL: Systemic therapy of cutaneous T-cell lymphoma (mycosis fungoides and the Sézary syndrome). Ann Intern Med 121:592, 1994
225. Edelson R, Berger C, Gasparro F, Jegasothy B, Heald P, Wintroub B, Vonderheid E, Knobler R, Wolff K, Plewig G, McKiernan G, Christiansen I, Oster M, Honigsmann H, Wilford H, Kokoschka E, Rehle T, Perez M, Stingl G, Laroche L: Treatment of cutaneous T cell lymphoma by extracorporal photochemotherapy. N Engl J Med 316:297, 1987
226. Heald PW: Photopheresis for cutaneous T-cell lymphoma. Ann NY Acad Sci 636:171, 1991
227. Zic J, Arzubiaga C, Salhany KE, Parker RA, Wilson D, Stricklin GP, Greer J, King LE: Extracorporal photopheresis for the treatment of cutaneous T-cell lymphoma. J Am Acad Dermatol 27:729, 1992
228. Armus S, Keyes B, Cahill C, Berger C, Crater D, Scaborough D, Klainer A, Bisaccia E: Photopheresis for the treatment of cutaneous T-cell lymphoma. J Am Acad Dermatol 23:898, 1990
229. Rook AH, Prystowsky MB, Cassin M, Boufal M, Lessin SR: Combined therapy for Sézary syndrome with extracorporal photochemotherapy and low dose interferon alpha therapy. Clinical molecular, and immunologic observations. Arch Dermatol 127:1535, 1991
230. Edelson RL: Photopheresis: A new therapeutic concept. Yale J Biol Med 62:565, 1989
231. Heald PW, Ferez MI, Christensen I, Dobbs N, McKiernan G, Edelson R: Photopheresis therapy of cutaneous T-cell lymphoma: The Yale-New Haven Hospital Experience. Yale J Biol Med 62:629, 1989
232. Edelson R, Heald P, Perez M: Photopheresis update. Prog Dermatol 25:1, 1991
233. Micaily B, Moser C, Vonderheid EC, Koprowski C, Lightfoot D, Markoe A, Brady L: The radiation treatment of early stage cutaneous T-cell lymphoma. Int J Rad Oncol Biol Phys 18:1333, 1990
234. Hoppe R: The management of mycosis fungoides at Stanford: Standard and innovative treatment programmes. Leukemia 5:46, 1991 (suppl)
235. Reddy S, Parker CM, Shidnia H, Gaffney MG, Blyton BD, Pruner LM, Kalasinski LA: Total skin electron beam radiation therapy for mycosis fungoides. Am J Clin Oncol 15:119, 1992
236. Becker M, Hoppe RT Knox SJ: Multiple courses of high-dose total skin electron beam therapy in the management of mycosis fungoides. Int J Rad Oncol Biol Phys 32:1445, 1995
237. Hallahan DE, Griem ML, Griem SF, Medenica M, Soltani K, Lorincz AL, Baron JM: Combined modality therapy for tumor stage mycosis fungoides: Results of a 10-year follow-up. J Clin Oncol 6:1177, 1988
238. Kaye FJ, Bunn PA Jr, Steinberg SM, Stocker JL, Ihde DC, Fischmann AB, Glatstein EJ, Schlechter GP, Phelps RM, Foss FM, Parlette HL, Anderson MJ, Sausville EA: A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. N Engl J Med 321:1784, 1989
239. Duvic M, Lemak NA, Redman JR, Eifel PJ, Tucker SL, Cabanillas FF, Kurzrock R: Combined modality therapy for cutaneous T-cell lymphoma. J Am Acad Dermatol 34:1022, 1996
240. Bigler RD, Crilley P, Micaily B, Brady LW, Topolsky D, Bulova S, Vonderheid EC, Brodsky I: Autologous bone marrow transplantation for advanced stage mycosis fungoides. Bone Marrow Transplant 7:133, 1991
241. Sterling JC, Marcus R, Burrows NP, Roberts SO: Erythrodermic mycosis fungoides treated with total body irradiation and autologous bone marrow transplatantion. Clin Exp Dermatol 20:73, 1995
242. Mercieca J, Matutes E, Dearden C, MacLennan K, Catovsky D: The role of pentostatin in the therapy of T-cell malignancies: Analysis of response rate in 145 patients according to disease subtype. J Clin Oncol 12:2588, 1994
243. Cummings FJ, Kyungmann K, Neiman RS, Comis RL, Oken MM, Weitzman SA, Mann RB, O'Connell MJ: Phase II trial of pentostatin in refractory lymphoma and cutaneous T-cell disease. J Clin Oncol 9:565, 1991
244. Grever MR, Bisaccia E, Scarborough DA, Metz EN, Neidhart JA: An investigation of 2-′deoxycoformycin in the treatment of cutaneous T-cell lymphomas. Blood 61:279, 1983
245. Saven A, Carrera CJ, Carson DA, Beutler E, Piro LD: 2-Chlorodeoxyadenosine: An actived agent in the treatment of cutaneous T-cell lymphoma. Blood 80:587, 1992
246. Kuzel TM, Hurria A, Samuelson E, Tallman MS, Roenigk HH Jr, Rademaker AW, Rosen ST: Phase II trial of 2-chlorodeoxyadenosine for the treatment of cutaneous T-cell lymphoma. Blood 87:906, 1996
247. O'Brien S, Kurzrock R, Duvic M, Kantarjian H, Stass S, Robertson LE, Estey E, Pierce S, Keating MJ: 2-Chlorodeoxyadenosine therapy in patients with T-cell lymphoproliferative disorders. Blood 84:733, 1994
248. Von Hoff DD, Dahlberg S, Hartstock RJ, Eyre HJ: Activity of fludarabine monophosphate in patients with advanced mycosis fungoides: A Southwest Oncology Group Study. J Natl Cancer Inst 82:1353, 1990
249. Cooper DL, Braverman IM, Sarris AH, Duvirage HJ, Saidman BH, Davis CA, Hait WN: Cyclosporine treatment of refractory T-cell lymphomas. Cancer 71:2335, 1993
250. Street ML, Muller SA, Pittelkow MR: Cyclosporine in the treatment of cutaneous T-cell lymphoma. J Am Acad Dermatol 23:1084, 1990
251. Totterman TH, Scheynius A, Killander A, Danersund A, Aim GV: Treatment of therapy -resistant Sézary syndrome with cyclosporine A: Suppression of pruritus, leukemic T-cell activation markers and tumor mass. Scand J Haematol 34:196, 1985
252. Puttick L, Pollock A, Fairburn E: Treatment of Sézary syndrome with cyclosporin A. J R Soc Med 76:1063, 1983
253. Maddox AM, Kahan BD, Tucker S, Kerman R, Jordan RE: Remission in skin infiltrate of a patient with mycosis fungoides treated with cyclosporin. J Am Acad Dermatol 12:952, 1985
254. Vonderheid EC, Thompson R, Smiles KA, Lattanand A: Recombinant interferon-alpha 2b in plaque-phase mycosis fungoides. Arch Dermatol 123:757, 1987
255. Bunn PA, Foon KA, Ihde DC, Longo DL, Eddy J, Winkler CF, Veach SR, Zeffren J, Sherwin S, Oldham RI: Recombinant leukocyte A-interferon; an active agent in advanced cutaneous T-cell lymphoma. Ann Intern Med 101:484, 1984
256. Kuzel T, Roenigk H, Samuelson E, Herrmann JJ, Hurria A, Rademaker AW, Rosen ST: Effectiveness of interferon-alpha-2a combined with phototherapy for mycosis fungoides and Sézary syndrome. J Clin Oncol 13:257, 1995
257. Foss FM, Ihde DC, Breneman DL, Phelps RM, Fischmann AB, Schechter GP, Linnoila I, Breneman JC, Cotelingam JD, Ghosh BC, Steinberg SM, Lynch JW, Phares JC, Stocker JL, Bastian A, Sausville EA: Phase II study of pentostatin and intermittent high dose of Interferon alpha-2a in advanced mycosis fungoides/Sézary syndrome. J Clin Oncol 10:1907, 1992
258. Foss F, Ihde DC, Linnoila IR, Fischmann AB, Schechter GP, Cotelingam JD, Steinberg SM, Ghosh BC, Stocker JL, Bastian A, Phares JC, Sausville EA: Phase II trial of fludarabine phosphate and Interferon alpha-2a in advanced mycosis fungoides/Sézary syndrome. J Clin Oncol 12:2051, 1994
259. Miller RA, Levy R: Response of cutaneous T-cell lymphoma to therapy with hybridoma Monoclonal antibody. Lancet 2:226, 1981
260. Bertram JH, Gill PS, Levine AM, Boquiren D, Hoffman FM, Meyer P, Mitchell MS: Monoclonal antibody T101 in T-cell malignacies: A clinical, pharmacokinetic and immunologic correlations. Blood 68:752, 1986
261. Boven E, Lindmo T, Mitchell JB, Bunn PA Jr: Selective cytotoxicity of 125 I-labeled monoclonal antibody T101 in human malignant T-cell lines. Blood 67:429, 1986
262. Rosen ST, Zimmer AM, Goldman-Leikin R, Gordon LI, Kazikiewicz JM, Kaplan EH, Variakojis D, Marder RJ, Dykewicz MS, Piergies A, Silverstein EA, Roenigk HH, Spies SM: Radioimmunodetection and radioimmunotherapy of cutaneous T-cell lymphomas using an 131 I-labeled monoclonal antibody: An Illinois Cancer Council Study. J Clin Oncol 5:562, 1987
263. LeMaistre CF, Rosen S, Frankel A, Kornfeld S, Saria E, Meneghetti C, Drajesk J, Fishwild D, Scannon P, Byers V: Phase I trial of H65-RTA immunoconjugate in patients with cutaneous T-cell lymphoma. Blood 78:1173, 1991
264. Bunn PA, Morris DA: The therapeutic role of interferon and monoclonal antibodies in cutaneous T-cell lymphomas. J Invest Dermatol 95:209S, 1990 (suppl)
265. Dillman RO, Shawler DL, Dillman JB, Royston I: Therapy of chronic lymphocytic leukemia and cutaneous T-cell lymphomas with T101 monoclonal antibody. J Clin Oncol 2:881, 1984
266. Knox SJ, Levy R, Hodgkin'son S, Bell R, Brown S, Wood GS, Hoppe R, Abel EA, Steiman L, Berger RG, Gaiser C, Young G, Bindl J, Hanham A, Reichert T: Observations on the effect of chimeric anti CD4-monoclonal antibody in patients with mycosis fungoides. Blood 77:20, 1991
267. Chatterjee M, Mrozek E, Vaickus L, Oseroff A, Stoll H, Russell D, Kohler H, Foon KA: Antidiotype (Ab2) vaccine therapy for cutaneous T-cell lymphoma. Am NY Acad Sci 690:376, 1993
268. Carrasquillo JA, Mulshine JL, Bunn PA Jr, Reynolds JC, Foon KA, Schroff RW, Perentesis P, Steis RG, Keenan AM, Horowitz M, Larson SM: Indium-111 T101 monoclonal antibody is superior to iodine-131 T101 in imaging of cutaneous T-cell lymphomas. J Nucl Med 28:281, 1987
269. Carrasquillo JA, Bunn PA Jr, Keenan AM, Reynolds JC, Schroff RW, Foon KA, Ming-Hsu S, Gazdar AF, Mulshine JL, Oldham RK, Perentesis P, Horowitz M, Eddy J, James P, Larson SM: Radioimmunodetection of cutaneous T-cell lymphoma with 111 In-T101 monoclonal antibody. N Engl J Med 315:673, 1986
270. Marolleau JP, Baccard M,Flageul B, Rybojad M, Laroche L, Verola O, Brandely M, Morel P, Gisselbrecht C: High-dose recombinant interleukin-2 in advanced cutaneous T-cell lymphoma. Arch Dermatol 131:574, 1995
271. LeMaistre CF, Meneghetti C, Rosenblum M, Reuben J, Parker K, Shaw J, Deisseroth A, Woodworth T, Parkinson DR: Phase I trial of an interleukin-2 (IL-2) fusion toxin (DAB486IL-2) in hematologic malignacies expressing the IL-2 receptor. Blood 79:2547, 1992
272. Kuzel T, Foss F, LeMaistre C, Platanias L, Ratain M, Rook A, Saleh M, Schwartz G, Nichols J: Phase I trial of a diphtheria toxin (DT) fusion protein (DAB389IL-2) for the treatment of interleukin-2 receptor (IL-2R) expressing hematologic neoplasms. Blood 86:274a, 1995 (abstr, suppl I)
273. LeMaistre CF, Kuzel T, Foss F, Hesketh P, Saleh M, Platanias L, Schwartz G, Craig F, Toison K, Woodworth T: DAB389 IL-2 is well tolerated at does inducing response in IL-2 receptor expressing lymhomas. Blood 82:137a, 1993 (abstr, suppl 1)
274. Seragen 1993 Quarterly Report 22 November 1993. Holkingston, MA, Seragen Inc, 1993
275. Kemme DJ, Bunn PA: State of the art therapy of mycosis fungoides and Sézary syndrome. Oncology 1992, p 31
276. Thomsen K, Hammar H, Molin L, Volden G: Retinoids plus PUVA (RePUVA) and PUVA in mycosis fungoides, plaque stage. Acta Derm Venereol 69:536, 1989
277. Stern RS, Laird NL, Melski J, Parrish JA, Fitzpatrick TB, Bleich HL: Cutaneous squamous-cell carcinoma in patients treated with PUVA. N Engl J Med 310:1156, 1984
278. Stern RS, Parrish JA, Fitzpatrick TB: Ocular findings in patients treated with PUVA. J Invest Dermatol 85:269, 1985
279. Vowels BR, Cassin M, Boufal MH, Walsh LJ, Rook AH: Extracorporeal photochemotheray induces the production of tumor necrosis factor-α by monocytes: Implications for the theatment of cutaneous T-cell lymphoma and systemic sclerosis. J Invest Dermatol 98:686, 1992
280. Lim HW, Edelson R: Photopheresis for the treatment of cutaneous T-cell lymphoma. Hematol Oncol Clin North Am 9:1177, 1995
281. Rook AH, NaHass GT, Macelis BJ: Extracorporeal photochemotherapy in the treatment of cutaneous T-cell lymphomas and autoimmune disorders affecting the skin in photosensitizing compounds: Their chemistry, biology and clinical use. Ciba Found Symp 146:171, 1989
282. Jones G, Jhoppe RT, Glastein E: Electron beam treatment for cutaneous T-cell lymphoma. Hematol Oncol Clin North Am 9:1057, 1995
283. Trump JG, Wright KA, Evans WW: High energy electrons for the therapy of extensive superficial malignant lesions. Am J Radiol 69:623, 1953
284. Wilson LD, Licata AL, Braverman IM, Edelson RL, Heald PW, Feldman AM, Kacinski BM: Systemic chemotherapy and extra-corporeal photochemotherapy for T3 and T4 cutaneous T-cell lymphoma patients who have achieved a complete response to total skin electron beam therapy. Int J Rad Oncol Biol Phys 32:987, 1995
285. Seto S, Carrera CJ, Kubota M, Wasson B, Carson DA: Mechanism of deoxyadenosine and 2-chlorodeoxyadenosine toxicity in nondividing human lymphocytes. J Clin Invest 75:377, 1985
286. Nickoloff BJ, Basham TY, Merigan TC, Morhenn VB: Antiproliferative effect of recombinant α- and γ-interferons on cultured human keratinocytes. Lab Investigation 51:697, 1984
287. Saiki I, Dunegan MA, Fann AV, Koff WC: Regulatory effects on macrophages of human recombinant interferon-alpha. J Int Res 6:603, 1986
288. Dicken CN, Connolly SM: Systemic retinoids in dermatology. Mayo Clin Proc 57:51, 1982
289. Molin L, Thomsen K, Volden G, Jensen P, Knudsen E, Nyfors A, Schmidt H: Retinoids and systemic chemotherapy in cases of advanced mycosis fungoides. A report from the Scandinavian mycosis fungoides group. Acta Derm Venereol 67:179, 1987
290. Jones G, McLean J, Rosenthal D, Roberts J, Sauder DN: Combined theatment with oral etretinate and electron beam therapy in patients with cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome). J Am Acad Dermatol 26:960, 1992
291. Nagatani T, Kin ST, Baba N, Miyamoto H, Nakajima H, Katoh Y: A case of cutaneous T-cell lymphoma treated with recombinant interleukin 2 (rIL-2). Acta Derm Venereol 68:504, 1988
292. Rybojad M, Marolleau JP, Flageul B,Baccard M,Brandely M, Morel P, Gisselbrecht C: Successful interleukin-2 therapy of advanced cutaneous T-cell lymphoma (letter). Br J Dermatol 127:63, 1992
293. Hesketh P, Caguioa P, Koh H, Dewey H, Facada A, McCaffrey R, Parker K, Nylen P, Woodworth T: Clinical activity of cytotoxic fusion protein in the treatment of cutaneous T-cell lymphoma. J Clin Oncol 11:1682, 1993
294. Miller RA, Oseroff AR, Stratte PT, Levy R: Monoclonal antibody therapeutic trials in seven patients with T-cell lymphoma. Blood 62:988, 1983
295. Zackheim HS, Kashani-Sabet M, Hwang ST: Low-dose methotrexate to treat erythrodermic cutaneous T-cell lymphoma: Results in twenty-nine patients. J Am Acad Dermatol 34:626, 1996
296. Ross C, Tingsgaard P, Jorgensen H, Bejlsgaard GL: Interferon treatment of cutaneous T-cell lymphoma. Eur J Haematol 51:63, 1993